CIMAvax, is a therapeutic vaccine against non-small cell lung cancer in advanced stages.
Pharmaceutical form: Injectable suspension for intradermal use (ID)
Therapeutic indications: Treatment of patients with non-small cell lung carcinoma (NSCLC), in advanced stages (IIIb or IV), with objective clinical response or stable disease, after oncospecific treatment of first-line chemotherapy / radiation therapy, such as switch maintenance.
Cancer treatment with the therapeutic vaccine CIMAvax-EGF ® can contribute to significantly prolong the survival time of patients and their quality of life, bringing the fatal course of this disease closer to the course of non-communicable chronic diseases, where the patient undergoes their treatment for life.
This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary lung.
